{"name": "Resverlogix",
 "permalink": "resverlogix",
 "crunchbase_url": "http://www.crunchbase.com/company/resverlogix",
 "homepage_url": "",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@resverlogix.com",
 "phone_number": "403.254.9252",
 "description": "",
 "created_at": "Wed Jul 21 01:44:31 UTC 2010",
 "updated_at": "Wed Jul 21 01:45:28 UTC 2010",
 "overview": "\u003Cp\u003EResverlogix Corporation, a biopharmaceutical company, focuses on the development of novel therapeutics in cardiovascular diseases, as well as in related indications in vascular inflammation and Alzheimer\u0026#8217;s disease. Its development programs include NexVas Plaque Regression, a technology platform, which has completed a Phase Ia safety trial in humans with RVX-208 and progressed to a Phase Ib/IIa clinical trial for the development of drugs that increase ApoA-I to reduce the risk of cardiovascular diseases; NexVas Vascular Inflammation, a discovery stage technology that is in preclinical stages for the development of drugs that target molecular markers of inflammation; NexVas Alzheimer\u0026#8217;s Disease, a discovery stage technology, which is in Phase I clinical trials for the development of drugs that enhance ApoA-I for the stabilization and regression of Beta Amyloid Plaque; ReVas, a research stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases; and TGF-\u00c3\u0178 Shield, a preclinical stage therapeutic for the treatment of grievous proliferative diseases, such as cancer and fibrotic conditions. The company is headquartered in Calgary, Canada.\u003C/p\u003E",
 "image": null,
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Donald",
      "last_name": "J. McCaffrey",
      "permalink": "donald-j-mccaffrey",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "A.",
      "last_name": "Brad Cann",
      "permalink": "a-brad-cann",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$25M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.resverlogix.com/upload/latest_news/108/01/2010-03-29_seda_and_prospectus_final.pdf",
    "source_description": "illion SEDA Activated",
    "raised_amount": 25000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 3,
    "funded_day": 29,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Yorkville Advisors",
         "permalink": "yorkville-advisors",
         "image":
          {"available_sizes":
            [[[150,
               94],
              "assets/images/resized/0006/0873/60873v1-max-150x150.png"],
             [[228,
               144],
              "assets/images/resized/0006/0873/60873v1-max-250x250.png"],
             [[228,
               144],
              "assets/images/resized/0006/0873/60873v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "202, 279 Midpark Way SE",
    "address2": "",
    "zip_code": "T2X 1M2",
    "city": "Calgary, AB",
    "state_code": null,
    "country_code": "CAN",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "TSX:RVX"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}